Promethera Biosciences SA raised €17 million (US$22.7 million) in a Series B round last week to fund the first clinical trials of its allogeneic stem cell therapy for pediatric and adult liver disorders. It also received a further €6.6 million in loan financing from Belgium's Walloon region.